Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Increased by South Dakota Investment Council

South Dakota Investment Council raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 266.6% during the 4th quarter, Holdings Channel reports. The fund owned 80,886 shares of the medical equipment provider’s stock after purchasing an additional 58,820 shares during the period. South Dakota Investment Council’s holdings in Zimmer Biomet were worth $8,544,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in ZBH. World Equity Group Inc. acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at $256,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Zimmer Biomet by 17.0% during the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 34,447 shares of the medical equipment provider’s stock valued at $3,639,000 after purchasing an additional 5,000 shares during the period. Olympiad Research LP acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at $228,000. Callan Capital LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at $209,000. Finally, Camelot Portfolios LLC increased its position in shares of Zimmer Biomet by 15.7% during the 4th quarter. Camelot Portfolios LLC now owns 4,434 shares of the medical equipment provider’s stock valued at $468,000 after purchasing an additional 601 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The business has a 50-day moving average of $105.86 and a two-hundred day moving average of $107.45. The stock has a market capitalization of $20.88 billion, a P/E ratio of 23.57, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 earnings per share. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Barclays lowered their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Wells Fargo & Company lifted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.